首页> 美国卫生研究院文献>AAPS PharmSciTech >Prednisolone-Loaded PLGA Microspheres. In Vitro Characterization and In Vivo Application in Adjuvant-Induced Arthritis in Mice
【2h】

Prednisolone-Loaded PLGA Microspheres. In Vitro Characterization and In Vivo Application in Adjuvant-Induced Arthritis in Mice

机译:泼尼松龙负载的PLGA微球。在小鼠佐剂诱发的关节炎中的体外表征和体内应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This study aimed at preparation of a sustained-release steroidal treatment for chronic inflammatory conditions, such as rheumatoid arthritis. To achieve such a goal, biodegradable poly-lactide-co-glycolide prednisolone-loaded microspheres were prepared using o/w emulsion solvent evaporation method. Formulation parameters were adjusted so as to optimize the microsphere characteristics. The prepared microspheres exhibited smooth and intact surfaces, with average size range not exceeding 65 µm. The encapsulation efficiency percent of most microsphere formulations fell within the range of 25–68%. Drug release from these microspheres took place over 4 weeks, with near-to-zero-order patterns. Two successful formulations were chosen for the treatment of unilateral arthritis, induced in mice using Freund's complete adjuvant (FCA). Inflammatory signs of adjuvant arthritis included severe swelling of the FCA-injected limbs, in addition to many histopathological lesions. These included inflammatory cell infiltration, synovial hyperplasia, cartilage, and bone erosion. Parenteral administration of the selected formulae dramatically reduced the swelling of the FCA-injected limbs. In addition, histological examination revealed that the microsphere treatment protocol efficiently protected cartilages and bones of mice, injected with FCA initial and booster doses, from erosion. These results could not be achieved by a single prednisolone dose of 5 mg/kg.
机译:这项研究的目的是为类风湿关节炎等慢性炎症性疾病准备缓释类固醇药物。为了实现该目标,使用o / w乳液溶剂蒸发法制备了可生物降解的聚丙交酯-共-乙交酯乙泼尼松龙微球。调整配方参数以优化微球特性。制备的微球表面光滑完整,平均尺寸范围不超过65 µm。大多数微球制剂的包封效率百分比在25-68%的范围内。这些微球的药物释放历时4周,呈近零级分布。选择了两种成功的制剂来治疗单侧关节炎,该制剂是使用弗氏完全佐剂(FCA)在小鼠中诱发的。辅助性关节炎的炎症体征包括除许多组织病理学病变外,注射FCA的肢体严重肿胀。这些包括炎症细胞浸润,滑膜增生,软骨和骨侵蚀。肠胃外施用所选配方可显着减少FCA注射肢体的肿胀。此外,组织学检查显示,微球治疗方案可有效保护注射了FCA初始剂量和加强剂量的小鼠的软骨和骨骼免受侵蚀。单剂量泼尼松龙5 mg / kg不能达到这些结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号